Ascendis Pharma A/S ADR (NASDAQ: ASND) started the day on Wednesday, with a price decrease of -11.27% at $119.50, before settling in for the price of $134.68 at the close. Taking a more long-term approach, ASND posted a 52-week range of $85.29-$161.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 182.00% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -19.87%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 23.35%. This publicly-traded company’s shares outstanding now amounts to $56.61 million, simultaneously with a float of $55.88 million. The organization now has a market capitalization sitting at $6.76 billion. At the time of writing, stock’s 50-day Moving Average stood at $134.97, while the 200-day Moving Average is $133.81.
Ascendis Pharma A/S ADR (ASND) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Ascendis Pharma A/S ADR’s current insider ownership accounts for 1.30%, in contrast to 106.98% institutional ownership.
Ascendis Pharma A/S ADR (ASND) Earnings and Revenue Records
Ascendis Pharma A/S ADR’s EPS increase for this current 12-month fiscal period is 23.35% and is forecasted to reach -3.40 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -1.02% through the next 5 years, which can be compared against the -19.87% growth it accomplished over the previous five years trading on the market.
Ascendis Pharma A/S ADR (NASDAQ: ASND) Trading Performance Indicators
Let’s observe the current performance indicators for Ascendis Pharma A/S ADR (ASND). It’s Quick Ratio in the last reported quarter now stands at 0.44. The Stock has managed to achieve an average true range (ATR) of 5.81. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 19.71.
In the same vein, ASND’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -9.34, a figure that is expected to reach -1.37 in the next quarter, and analysts are predicting that it will be -3.40 at the market close of one year from today.
Technical Analysis of Ascendis Pharma A/S ADR (ASND)
If we take a close look at the recent performances of Ascendis Pharma A/S ADR (NASDAQ: ASND), its last 5-days Average volume was 0.91 million that shows progress from its year to date volume of 0.39 million. During the previous 9 days, stock’s Stochastic %D was recorded 16.47% While, its Average True Range was 6.20.
Raw Stochastic average of Ascendis Pharma A/S ADR (ASND) in the period of the previous 100 days is set at 13.15%, which indicates a major fall in contrast to 16.60% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 49.65% that was higher than 39.29% volatility it exhibited in the past 100-days period.
